Biotechnology company and drug delivery platform innovator
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected
for cannabidiol and all other nonpsychoactive cannabinoids. The company also
currently has patents pending for THC, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An
article discussing the company reads, “Lexaria Bioscience has 10 patents
granted with over 50 patents pending. Four of the granted patents focus on the
delivery of nicotine. The company is not partnering with the tobacco industry.
However, Bunka informed that Lexaria is exploring the potential use of its
DehydraTECH technology to help people stop smoking. . . . The company’s
technology has been shown to deliver nicotine to the brain quicker than
traditional delivery systems. The goal for Lexaria is to put nicotine into some
type of oral form to eliminate the need for inhalation and help people curb
their smoking habits. DehydraTECH studies in 2018 included two animal studies
that delivered pioneering results highlighting the improvements of nicotine
delivery to blood plasma and across the blood-brain barrier (http://ibn.fm/QOjnR).”
To view the full article, visit http://ibn.fm/nm4RB
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and quicker onset of lipophilic active molecules. Lexaria has
ten patents granted in the United States and Australia, and has filed over 50
patent applications worldwide across 10 patent families. Lexaria’s technology
provides more rapid delivery to the bloodstream, as well as important
taste-masking benefits for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
